Valvular Heart Disease (VHD) has been described as ‘the next cardiac epidemic’ and is the second most frequent cardiovascular condition after hypertension and coronary heart disease in high outcome countries, and the first most frequent worldwide. Canadian investigators and centers have been at the forefront of research, innovation, and knowledge translation in the field of VHD for the past three decades and are thus in excellent position to maintain and expand their leadership for the realization of clinical trials in VHD in Canada and internationally. The ACT Canada consortium will be key to achieve this goal and will considerably accelerate and enhance the capacity of this VHD trial network (PACT-V) for the realization of trials in patients with VHD to validate new interventional or pharmacological therapies for these frequent and serious diseases.